Lv3
258 积分 2025-05-06 加入
ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial
2天前
已完结
Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial
2天前
已完结
Debate 3: Metastasis Directed Therapy in Oligometastatic Prostate Cancer
13天前
已完结
Destroy or delay: hormonal therapy in oligometastatic prostate cancer
14天前
已完结
Oligometastatic prostate cancer - bridging the gap between localized and metastatic disease
14天前
已完结
Cancer burden and control in China: landscape, trends and challenges
22天前
已完结
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer
27天前
已完结
PRECISE Version 2: Essential Tips for Prostate Cancer Monitoring Using MRI
1个月前
已完结
PI3K/AKT inhibitors aggravate death receptor-mediated hepatocyte apoptosis and liver injury
1个月前
已完结
Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors
1个月前
已完结
基于微生物发酵的人参皂苷转化研究进展
1年前
已采纳
皖公网安备34019202002308
